We read the article by Trifilio et al.
1 with great interest. In that article, 58 patients were identified with zygomycosis. Of these 58 patients, 56 received voriconazole as primary or secondary prophylaxis. Invasive fungal infections, particularly Aspergillus, are one of the leading causes of death in patients undergoing allogeneic stem cell transplantation (alloSCT). Both voriconazole and caspofungin have been shown to be effective antifungal agents against aspergillosis.
2 For this reason, in addition to the increasing prevalence of fluconazole-resistant Candida glabrata and Candida krusei, many haematopoietic stem cell transplant recipients are receiving voriconazole for fungal prophylaxis.
We present here a 54-year-old male patient who was found to be severely pancytopenic in May 2006. The patient was diagnosed with myelodysplastic syndrome and was treated with 400 mg thalidomide daily. The patient received 200 mg voriconazole b.i.d., for fungal prophylaxis. In September 2006, his chest X-ray was normal while still being neutropenic. In October 2006, the patient underwent myeloablative alloSCT from a HLA-identical sibling. On day À4 the patient developed febrile neutropenia. A chest X-ray showed bilateral airspace disease with pleural effusion. Empirical antibacterial treatment was started. Caspofungin (70 mg on day 1, then 50 mg daily) was added to voriconazole. The patient was intubated because of respiratory and liver failure on day þ 2. Defibrotide was initiated for probable veno occlusive disease (VOD) of the liver. Bronchoalveolar lavage (BAL) and diagnostic thoracentesis were performed on day þ 7. Fungal elements, Pneumocystis carinii, or bacteria were not detected by microscopic evaluation. The patient died on day þ 9 because of multi-organ failure when all cultures were negative. One month later, Rhizopus spp. were isolated only after broth enrichment in the pleural fluid (identification was carried out by DNA sequencing at the Laboratory of Medicine and Pathology at Mayo Clinic, Rochester, MN, USA). At the same time, the sputum culture also grew Rhizomucor spp.
The incidence of zygomycosis in immunocompromised patients has been increasing. [3] [4] [5] [6] [7] Voriconazole and caspofungin are not effective against Zygomycetes spp.
2 There is a rising concern about whether there is a causal relationship between voriconazole use and increased infections of Zygomycetes spp.
1,3-6 Ninety-six percent of patients with zygomycosis were on voriconazole in the Trifilio et al. 3 that zygomycosis occurred greater than 90 days post transplant. Our patient was on voriconazole prophylaxis because of prolonged neutropenia. In contrast to the vast majority of patients, the patient developed zygomycosis during the very early post-transplant period (perhaps during the conditioning regimen). As with our patient, lung and sinuses are the most common sites involved with Zygometes spp. infections.
1,3
Despite aggressive treatment, immediate diagnosis can be very difficult since fungal culture identification requires time. Therefore, empirical treatment is important. Amphotericin B and the recently approved posaconazole can be effective for zygomycosis. 1, 8, 9 Prophylactic antifungal treatment is guided by risk factors. Our patient had only one risk factor (prolonged neutropenia) and therefore was 'wisely' put on voriconazole. However, the patient developed zygomycosis and died immediately post-transplant. We believe that voriconazole prophylaxis should be thought of as one of the risk factors for zygomycosis. Voriconazole prophylaxis appears not only to increase zygomycosis but also changes the time of its occurrence. In patients on voriconazole prophylaxis, regardless of the stage of transplantation, any new sinopulmonary infections should prompt the empirical use of posaconazole and/or amphotericin B instead of agents not active against Zygomycetes spp., such as caspofungin. 
